KRRO Korro Bio, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1703647 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-82.5%
TTM net income YoY-20.0%
TTM EPS YoY5.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-8,467.3%
Net margin-8,214.5%
FCF margin-4,943.8%
EBITDA margin-8,325.8%
Returns
ROE-113.3%
ROA-68.5%
ROIC (approx.)-140.5%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets40.3%
Debt / equity0.00x
Current ratio7.30x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.60x
Accruals ratio-27.4%
Payout ratio—
Capex / revenue13.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $6.39M | $2.27M | $0 | $0 | $14.07M |
| R&D expense | $65.58M | $63.64M | $57.25M | $42.20M | $60.92M |
| SG&A expense | $28.16M | $30.55M | $27.28M | $16.80M | $37.18M |
| Operating income | -$121.86M | -$91.91M | -$84.53M | -$59.00M | -$84.03M |
| Interest expense | — | — | — | $961,000 | $764,000 |
| Pretax income | -$116.62M | -$83.44M | -$81.14M | -$58.02M | -$84.67M |
| Income tax | $637,000 | $141,000 | $27,000 | $10,000 | $15,000 |
| Net income | -$117.26M | -$83.58M | -$81.17M | -$58.03M | -$84.69M |
| EBITDA | -$117.58M | -$88.34M | -$80.90M | -$56.49M | -$81.26M |
| EPS (basic) | -12.48 | -9.37 | -53.08 | -227.42 | -2.47 |
| EPS (diluted) | -12.48 | -9.37 | -53.08 | -227.42 | -2.47 |
| Weighted avg. shares (diluted) | 9.40M | 8.92M | 1.53M | 255,175 | 34.35M |
| Banking | |||||
| Net interest income | — | — | $0 | -$118,000 | — |
| Balance sheet | |||||
| Cash & equivalents | $21.82M | $55.64M | $166.15M | $36.33M | $79.64M |
| Short-term investments | $53.33M | $70.45M | $0 | $18.91M | $51.07M |
| Current assets | $82.37M | $131.53M | $172.73M | $57.08M | $134.75M |
| PP&E, net | $8.16M | $27.71M | $15.66M | $9.87M | $5.52M |
| Total assets | $113.51M | $226.24M | $221.66M | $73.74M | $185.36M |
| Current liabilities | $11.94M | $14.96M | $19.48M | $8.70M | $11.43M |
| Short-term debt | — | — | — | $10.00M | $833,000 |
| Total liabilities | $62.07M | $65.83M | $51.75M | $8.91M | $54.53M |
| Shareholders' equity | $51.44M | $160.41M | $169.91M | -$99.03M | -$42.21M |
| Shares outstanding | 9.42M | 9.38M | 8.02M | 268,468 | 34.61M |
| Cash flow statement | |||||
| Operating cash flow | -$78.56M | -$60.07M | -$67.28M | -$53.65M | -$76.06M |
| Capital expenditure | $518,000 | $17.90M | $7.84M | $5.14M | $2.91M |
| Free cash flow | -$79.08M | -$77.98M | -$75.12M | -$58.78M | -$78.97M |
| Investing cash flow | $43.99M | -$123.35M | $11.16M | $11.06M | -$66.13M |
| Financing cash flow | $685,000 | $69.36M | $187.76M | $18,000 | $1.36M |
| Depreciation & amortization | $4.28M | $3.56M | $3.63M | $2.51M | $2.77M |
| Stock-based compensation | $7.66M | $4.46M | $2.38M | $1.14M | $21.75M |
Free plan shows the latest 5 periods; Pro shows all 9 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.